# EDGAR Filing Document

**Accession Number:** 0001491719
**File Stem:** 0000908834-26-000072
**Filing Date:** 2026-2
**Character Count:** 8081
**Document Hash:** 5c7a0a89140b321ee216a8e7bd698661
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000908834-26-000072.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0000908834-26-000072

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silence Therapeutics plc
- **CENTRAL INDEX KEY:** 0001479615
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92205
- **FILM NUMBER:** 26610684

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP
- **BUSINESS PHONE:** 44-0-20-3457 6900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lombard Odier Asset Management (USA) Corp
- **CENTRAL INDEX KEY:** 0001491719

**ORGANIZATION NAME:**
- **EIN:** 061603711
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 452 FIFTH AVENUE, 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 212-295-6200

**MAIL ADDRESS:**
- **STREET 1:** 452 FIFTH AVENUE, 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Issuer:** Silence Therapeutics plc

**Title of Class of Securities:** Ordinary Shares, par value GBP 0.05 per share (the "Shares")

**CUSIP Number:** G8128Y157

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Lombard Odier Asset Management (USA) Corp | Names of Reporting Persons<br>Lombard Odier Asset Management (USA) Corp |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>5935955 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>5935955 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5935955 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5935955 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.2% | Percent of Class Represented by Amount in Row (9)<br>4.2% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, OO | Type of Reporting Person (See Instructions)<br>IA, OO |

---

**Item 1(a). Name of Issuer:**
Silence Therapeutics plc

**Item 1(b). Address of Issuer's Principal Executive Offices:**
12 Hammersmith Grove, London, United Kingdom, W6 7AP

**Item 2(a). Name of Person Filing:**
This statement is filed by Lombard Odier Asset Management (USA) Corp (the "Investment Advisor"), with respect to ADSs (as defined in Item 4) held by 1798 Volantis Fund Ltd, 1798 UK Small Cap Best Ideas Fund Ltd and one or more managed accounts. The Investment Advisor serves as the investment advisor to each of the foregoing.

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of the Investment Advisor is 452 Fifth Avenue, 25th Floor, New York, NY 10018.

**Item 2(c). Citizenship:**
The Investment Advisor is a corporation organized under the laws of the State of Delaware.

**Item 2(d). Title of Class of Securities:**
Ordinary Shares, par value GBP 0.05 per share (the "Shares")

**Item 2(e). CUSIP Number:**
G8128Y157

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As of the date requiring the filing of this statement, the Investment Advisor beneficially owns an aggregate of 5,935,955 Shares, inclusive of 1,978,650 American Depositary Shares ("ADSs"), each of which represents, and at the holder's option is convertible into, three Shares.
The percentages used herein and in the rest of this Schedule 13G are calculated based upon 141,701,848 Shares issued and outstanding as of October 30, 2025, as reported by the Company in its Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.

**(b) Percent of class:**

4.2

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

5,935,955

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

5,935,955

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Lombard Odier Asset Management (USA) Corp**

**Date:** 02/09/2026

**By:** /s/ Elyse Strauss

**Name & Title:** Authorized Signatory